Actively Recruiting
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning With Post-Transplant Cyclophosphamide for Treating Hematological Diseases
Led by Masonic Cancer Center, University of Minnesota · Updated on 2025-07-01
56
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a Phase II study focused on patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen includes cyclophosphamide, fludarabine, and total body irradiation (TBI) followed by stem cell infusion from related, unrelated, or partially matched family donors. The study aims to assess the outcomes of this treatment approach, including rates of acute and chronic graft-versus-host disease (GVHD) over 12 months. The treatment involves a preparative regimen with cyclophosphamide, fludarabine, and a single fraction of total body irradiation given prior to transplant. On day 0, patients receive an infusion of peripheral blood stem cells or bone marrow cells according to donor preference. After transplant, patients receive post-transplant cyclophosphamide, sirolimus starting from day +5 through day +60 with a loading dose and maintenance dosing, and mycophenolate mofetil from day +5 through day +35. Dosing varies by patient characteristics such as weight and age. Participants will be closely monitored throughout the study with evaluations of acute and chronic GVHD at 12 months, relapse rates at 100 days, overall survival up to 72 months, and transplant-related mortality at 12 months. Organ function, infection status, and other safety parameters will be assessed. The study includes ongoing follow-up to observe treatment effects and safety outcomes over time.
CONDITIONS
Brief Title
Allo HSCT Using RIC and PTCy for Hematological Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 0 to 75 years with Karnofsky score 270% if 16 years or older, or Lansky score 250 if under 16 years
- Suitable donor: 5/6 or 6/6 related donor, 7-8/8 HLA matched donor, or haplotype matched related donor
- Diagnosed with eligible hematological diseases including certain leukemias, lymphomas, myelodysplastic syndromes, myeloproliferative neoplasms, and related disorders
- For acute leukemias, must be in remission by morphology and without minimal residual disease by certain tests
- Must meet disease-specific remission and risk criteria as detailed in the study
- Adequate organ function including liver, kidney, heart, and lung function within specified limits
- HIV infection allowed if viral load undetectable and management plan established
- Females and males of childbearing potential must agree to use birth control during treatment
- Voluntary written consent obtained
You will not qualify if you...
- Pregnant or breastfeeding women
- Untreated active infections
- Active central nervous system malignancy
- CML in blast crisis phase
- Progressive intermediate or high grade non-Hodgkin lymphoma, mantle cell lymphoma, or Hodgkin disease on salvage therapy
- Less than 3 months since prior myeloablative transplant
- Evidence of progressive disease by imaging or biopsy, except certain PET activity without CT changes
- Other conditions or features that may increase risk or interfere with treatment as per study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 days
Participants receive conditioning treatment including allopurinol from day -7 to day 0, fludarabine from day -6 to day -2, cyclophosphamide on day -6, and total body irradiation on day -1 to prepare for stem cell transplant.
Daily visits for treatment administration from day -7 to day 0
Duration - 1 day
Participants receive peripheral blood stem cell or bone marrow cell transplant on day 0.
1 visit (in-person) on transplant day
Duration - 31 days
Participants receive cyclophosphamide on days +3 and +4, and begin immunosuppressive medications including sirolimus and mycophenolate mofetil from day +5 through day +35 to prevent graft-versus-host disease.
Visits on days +3, +4, and daily or frequent visits from day +5 to day +35
Duration - 56 days
Participants continue sirolimus treatment daily from day +5 to day +60 to maintain immunosuppression.
Regular visits during days +5 to +60
Duration - Up to 12 months
Participants are monitored for transplant outcomes including graft-versus-host disease, relapse, and survival for up to 12 months and beyond.
Regular follow-up visits during the first year after transplant
Trial Site Locations
Total: 1 location
1
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
Research Team
M
Mark Juckett
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here